Compare Novo Nordisk A/S (NVO) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Teucrium Soybean Fund — how do they compare? Novo Nordisk A/S trades at $46.46 (market cap $207.85B), while Teucrium Soybean Fund trades at $25.05. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SOYB | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.98 | $26.28 |
52-Week Low | $35.29 | $21.46 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
SOYB trades at $25.24, up 0.28% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights agricultural sector tailwinds from China's crop purchase pledge, though geopolitical risks from Middle East tensions pose headwinds.
The outlook hinges on sector-specific catalysts like export demand, but absent financial data obscures valuation. Risks include commodity volatility and geopolitical spillovers. Investors require updated SEC filings to assess profitability and growth prospects amid mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
